新辅助化疗对乳腺癌激素受体ER、PR表达的影响  

Influence of Neoadjuvant Chemotherapy on the Expression of Hormone Receptors ER、PR in Breast Cancer

作　　者：赵波涛[1] 罗庆丰[1] 高玟[1] 黄传生[1] 涂侃[1] 

机构地区：[1]江西省肿瘤医院,330029

出　　处：《实用癌症杂志》2014年第1期8-9,共2页The Practical Journal of Cancer

基　　金：江西省卫生厅课题(编号20073128)

摘　　要：目的探讨新辅助化疗对乳腺癌激素受体ER、PR表达的影响。方法应用MaxVinsion免疫组织化学技术,检测32例浸润性导管癌乳腺患者新辅助化疗前、新辅助化疗后ER、PR表达情况。结果 32例乳腺浸润性导管癌新辅助化疗前与化疗后检测结果完全相同:5例不表达ER,8例ER+,12例ER++,7例ER+++;6例不表达PR,7例PR+,12例PR++,7例PR+++。同时ER、PR阳性表达具有良好一致性,32例患者中ER、PR阳性表达间具有显著相关性。结论乳腺癌患者新辅助化疗前后激素受体ER、PR表达结果完全一致,新辅助化疗安全可行。Objective To explore the influence of neoadjuvant chemotherapy on the expression of hormone receptors ER、PR in breast cancer .Methods Expression of ER、PR of 32 infitrating ductal carcinoma .patients before and after new adju-vant chemotherapy were detected by Maxvinsion immunohistochemistry .Results Expression of ER、PR of 32 infitrating ductal carcinoma patients before and after new adjuvant chemotherapy were the same .Negative expression of ER was observed in 5,ex-pression of ER +was observed in 8,ER ++in 12 and ER +++in 7.Negative expression of PR was observed in 6,expres-sion of PR +was observed in 7,PR ++in 12 and PR +++in 7.The positive expression of ER and PR was consistent ,and correlation comparison of the positive expression rate of ER and PR was important .Conclusion Expression of hormone receptors ER、PR in breast cancer before and after new adjuvant chemotherapy are the same .Neoadjuvant chemotherapy is safe .

关 键 词：浸润性导管癌 新辅助化疗 免疫组织化学技术 ER蛋白 PR蛋白 

分 类 号：R737.9[医药卫生—肿瘤]